David Vilanova
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
-
- Peptidase Inhibition and Analysis
Papers in
-
- Multiple Myeloma Research and Treatments 3
-
- Protein Degradation and Inhibitors 2
- Histone Deacetylase Inhibitors Research 2
- Co-authors
- Enrique M. Ocio (4 shared papers)Mercedes Garayoa (4 shared papers)Laura San‐Segundo (4 shared papers)Patricia Maiso (4 shared papers)Enrique de Álava (3 shared papers)Atanasio Pandiella (4 shared papers)Jesús F. San Miguel (4 shared papers)Teresa Hernández‐Iglesias (3 shared papers)
- Journals
- Blood (3 papers)JCO Oncology Practice (1 paper)Journal of Clinical Oncology (1 paper)Journal of Geriatric Oncology (1 paper)The Lancet Regional Health - Europe (1 paper)
- Partner nations
- SpainUnited StatesAndorra
In The Last Decade
David Vilanova
9 papers receiving 254 citations
Peers
Comparison fields: 5 of 61
- Hematology 113
- Oncology 84
- Cancer Research 43
- Biotechnology 22
- Molecular Biology 162
Countries citing papers authored by David Vilanova
This map shows the geographic impact of David Vilanova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Vilanova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Vilanova more than expected).
Fields of papers citing papers by David Vilanova
This network shows the impact of papers produced by David Vilanova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Vilanova. The network helps show where David Vilanova may publish in the future.
Co-authors
The 25 scholars most cited alongside David Vilanova, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 130 | |
| 2 | 2008 | 73 | |
| 3 | 2021 | 16 | |
| 4 | 2022 | 13 | |
| 5 | 2020 | 11 | |
| 6 | 2022 | 10 | |
| 7 | 2022 | 6 | |
| 8 | 2008 | 3 | |
| 9 | 2007 | 2 | |
| 10 | 2025 | 0 | |
| 11 | 2024 | 0 |
About David Vilanova
David Vilanova is a scholar working on Hematology, Molecular Biology, Cancer Research, Dermatology and Pulmonary and Respiratory Medicine, having authored 11 papers that have together received 264 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (3 papers), Protein Degradation and Inhibitors (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Economic and Financial Impacts of Cancer (2 papers), Synthesis and Biological Activity (2 papers), Skin Protection and Aging (2 papers), Renal cell carcinoma treatment (2 papers) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Hematology (113 citations), Oncology (84 citations), Cancer Research (43 citations), Biotechnology (22 citations) and Molecular Biology (162 citations). David Vilanova has collaborated with scholars based in Spain, United States and Andorra. Frequent co-authors include Enrique M. Ocio, Mercedes Garayoa, Laura San‐Segundo, Patricia Maiso, Enrique de Álava, Atanasio Pandiella, Jesús F. San Miguel, Teresa Hernández‐Iglesias, Peter Atadja and Diego Fernández‐Lázaro. Their work appears in journals such as Blood, JCO Oncology Practice, Journal of Clinical Oncology, Journal of Geriatric Oncology and The Lancet Regional Health - Europe.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.